Segment & Geographic Data Quant-Grade Normalized Data API & CSV Delivery

Design Therapeutics Inc's Business Segments

Design Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Reportable Segments
1
Per the company's own filing, this quarter
Largest Segment
Single Reporting Segment
Total Revenue
-
Consolidated, this quarter
Regions Reported
-
Geographic regions, this quarter

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/DSGN/segments
https://api.csimarket.com/api/v1/companies/DSGN/geographic
https://api.csimarket.com/api/v1/companies/DSGN/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Dataset & schema
https://api.csimarket.com/api/datasets/business_segments
https://api.csimarket.com/api/schema/business_segments
https://api.csimarket.com/api/meta/business_segments

Revenue Share by Reportable Segment -

0%largest
  • Single Reporting Segment0%

Revenue by Reportable Segment -

SegmentPeriodRevenue
(Millions)
% of TotalOperating Income
Single Reporting Segment$ 6--

Annual Results

Revenue Share by Reportable Segment -

0%largest
  • Single Reporting Segment0%

Revenue by Reportable Segment -

SegmentPeriodRevenue
(Millions)
% of TotalOperating Income
Single Reporting Segment$ 6--

Description of Design Therapeutics Inc

Design Therapeutics Inc is a biotechnology company that is focused on developing transformative treatments for serious degenerative conditions that are caused by RNA dysregulation. The company was founded in 2017 by two leading RNA-targeting scientists from Scripps Research, Matthew Disney, PhD, and Adrian Krainer, PhD, along with entrepreneur Jean-Pierre Sommadossi, PhD, who serves as the CEO.

Design Therapeutics is headquartered in San Diego, California and is primarily focused on developing small molecule drugs that specifically target RNA molecules that are malfunctioning in a variety of disease states. RNA is a critical component of gene expression and can play a causal role in many diseases, including neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease, as well as genetic disorders such as myotonic dystrophy.

The company has a proprietary platform technology called 'DTx RNA Targeting Platform' that enables precision medicine technologies for rigorous target identification and selection followed by the design precise small molecules as potential therapeutics. The platform encompasses in-depth genomics data, small molecule pharmacological properties, and proprietary algorithms for identifying potential RNA targets.

One of the lead programs for Design Therapeutics is in the development of DM1, a small molecule investigational therapy for myotonic dystrophy type 1 (DM1). DM1 is an inherited neuromuscular disorder that affects multiple organs and systems of the body, including the nervous system, heart, and muscle. There is currently no cure for DM1, only supportive therapies for the symptoms. Design Therapeutics is focused on developing a small molecule DM1 drug candidate that selectively inhibits the abnormal protein produced by DM1's genetic mutation.

Furthermore, Design Therapeutics has various collaborations with other biotech companies and institutions. In 2021, it announced a partnership with Regeneron to utilize its precision medicine platform towards discovering RNA-targeting therapeutics.

In summary, Design Therapeutics Inc is a biotechnology company that is focused on developing small molecule drugs that target RNA molecules that are implicated in degenerative diseases, with emphasis on neuromuscular disorders. With a proprietary platform technology and an experienced team, the company aims to bring transformative treatments to the clinic.
Design Therapeutics Inc: Comprehensive Overview of Segments, Products, and Services

Company Overview:
Design Therapeutics Inc is a clinical-stage biotechnology company specializing in the development of small molecules aimed at treating serious and degenerative disorders linked to nucleotide repeat expansions. These conditions often stem from genetic mutations where repetitive sequences of nucleotides in DNA can lead to the production of toxic RNA and proteins. Design Therapeutics employs a unique platform technology that targets the underlying RNA molecules implicated in these diseases to mitigate their pathological effects directly.

Segments:
Design Therapeutics operates primarily within the pharmaceutical industry, with a concentrated focus on the following segments:

1. Prescription Drugs: This segment is the core of Design Therapeutics business model, emphasizing the discovery and development of drug candidates that tackle significant unmet medical needs. Prescription medications typically provide higher margins and a greater opportunity for innovation compared to over-the-counter drugs, making this focus strategically advantageous for the company.

2. Rare and Genetic Diseases: The company zeroes in on rare genetic diseases characterized by nucleotide repeat expansions, positioning itself to address critical gaps in treatment options where existing therapies are ineffective or unavailable.

3. Clinical Development: As a clinical-stage company, Design Therapeutics is deeply invested in conducting clinical trials to validate the safety and efficacy of their product candidates for eventual regulatory approval and commercialization.

Products:
Design Therapeutics has assembled a promising pipeline of therapeutic candidates, each designed to combat specific degenerative disorders associated with nucleotide repeat expansions. The leading products include:

1. DTx-201: The flagship product candidate, DTx-201 is designed to target Spinocerebellar Ataxia Type 3 (SCA3), a severe neurodegenerative disorder that impairs motor functions and coordination. This condition currently lacks effective treatment options. DTx-201 has demonstrated encouraging results in preclinical studies and is currently undergoing Phase 1 clinical trials to establish its safety and efficacy in human subjects.

2. Additional Pipeline Candidates: Beyond DTx-201, Design Therapeutics is pursuing multiple other drug candidates in preclinical stages focused on various genetic disorders, including but not limited to:
- Huntingtons Disease: Targeting the underlying genetic mechanisms of this progressive neurodegenerative disease.
- Myotonic Dystrophy Type 1 and Type 2: Addressing muscle wasting and myotonia associated with these genetic disorders.

The company’s approach centers around the precise design of small molecules that selectively interact with the problematic RNA, thereby preventing the formation of toxic aggregates that lead to cellular dysfunction and degeneration.

Services:
To support its product development ambitions, Design Therapeutics Inc provides a suite of services designed to foster innovation and streamline the path to commercialization:

1. Early-Stage Research and Development: The company engages in advanced R&D initiatives to identify novel drug targets. This involves a comprehensive understanding of the intricate relationships between genetic mutations and their resultant pathogenic RNA species.

2. Pre-Clinical Development: After identifying lead candidates, Design Therapeutics conducts rigorous preclinical testing to assess the safety, toxicity, and therapeutic potential of these compounds in animal models. This stage is critical for refining the drug candidate before it enters human trials.

3. Clinical Development: The organization designs, oversees, and conducts clinical trials to test the safety and clinical efficacy of its drug candidates. The goal at this stage is to generate robust clinical data to support regulatory submissions and subsequent marketing approvals.

4. Commercialization Strategy: Upon successful clinical development, Design Therapeutics aims to navigate the commercialization landscape, which may involve forming strategic partnerships with established pharmaceutical companies or deploying its own commercialization efforts. The focus is on maximizing the potential market impact of its products while ensuring their availability to patients in need.

Conclusion:
Design Therapeutics Inc is poised to make significant strides in treating genetic disorders associated with nucleotide repeat expansions. Through its focused segments, innovative product pipeline, and comprehensive set of services, the company is well-equipped to contribute meaningfully to the advancement of genetic therapies that address critical patient needs in this underserved domain.
Get the full CSIMarket dataset: Subscribe API Connect Your AI